Global Anti-Anxiety Drug Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Anti-Anxiety Drug Market is presumed to reach the market size of nearly USD 25.01 Billion by 2032 from USD 15.74 Billion in 2023 with a CAGR of 5.28% under the study period 2024 - 2032.

Anti-anxiety drugs, also known as anxiolytics, are medications designed to relieve symptoms of anxiety disorders. These disorders are mental health conditions characterized by excessive worry, fear, or nervousness, often leading to significant distress or impairment in daily functioning. These drugs work by affecting the central nervous system to reduce the intensity of anxiety symptoms.

MARKET DYNAMICS

The anti-anxiety drug market is propelled by several interconnected factors. Rising global awareness and acceptance of mental health issues, coupled with an increasing prevalence of anxiety disorders, contribute to a growing demand for anti-anxiety medications. Ongoing advancements in pharmaceutical research and development lead to the discovery of novel compounds and formulations, enhancing the effectiveness of these medications. The aging global population, characterized by a higher susceptibility to anxiety disorders, further boosts market growth. Additionally, modern lifestyles with elevated stress levels, expanding healthcare infrastructure, and changing regulatory environments supporting mental health research contribute to the market's expansion. Increased prescription rates and technological advancements in treatment modalities, such as telemedicine and digital health, also play pivotal roles. However, challenges include concerns about over-prescription, potential side effects, and the need for a comprehensive mental health approach encompassing therapy and lifestyle interventions.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of anti-anxiety drug. The growth and trends of anti-anxiety drug industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the anti-anxiety drug market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

Selective Serotonin Reuptake Inhibitors (SSRIs)
Benzodiazepines
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
Beta Blockers

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies/Drug Stores
Online Pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Anti-Anxiety Drug market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Anti-Anxiety Drug market include Pfizer Inc., Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, AstraZeneca plc, Roche Holding AG, Forest Laboratories (a subsidiary of Allergan, now part of AbbVie), Bristol Myers Squibb Company, Sanofi S.A., Lundbeck A/S. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112113495

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . ANTI-ANXIETY DRUG - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Distribution Channel
- 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL ANTI-ANXIETY DRUG MARKET ANALYSIS BY DRUG CLASS

5.1 Overview by Drug Class
5.2 Historical and Forecast Data
5.3 Analysis by Drug Class
5.4 Selective Serotonin Reuptake Inhibitors (SSRIs) Historic and Forecast Sales by Regions
5.5 Benzodiazepines Historic and Forecast Sales by Regions
5.6 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) Historic and Forecast Sales by Regions
5.7 Beta Blockers Historic and Forecast Sales by Regions

6 . GLOBAL ANTI-ANXIETY DRUG MARKET ANALYSIS BY DISTRIBUTION CHANNEL

6.1 Overview by Distribution Channel
6.2 Historical and Forecast Data
6.3 Analysis by Distribution Channel
6.4 Hospital Pharmacies Historic and Forecast Sales by Regions
6.5 Retail Pharmacies/Drug Stores Historic and Forecast Sales by Regions
6.6 Online Pharmacies Historic and Forecast Sales by Regions

7 . GLOBAL ANTI-ANXIETY DRUG MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1. Overview, Historic and Forecast Data Sales Analysis
- 7.3.2. North America By Segment Sales Analysis
- 7.3.3. North America By Country Sales Analysis
- 7.3.4. United State Sales Analysis
- 7.3.5. Canada Sales Analysis
- 7.3.6. Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1. Overview, Historic and Forecast Data Sales Analysis
- 7.4.2. Europe by Segment Sales Analysis
- 7.4.3. Europe by Country Sales Analysis
- 7.4.4. United Kingdom Sales Analysis
- 7.4.5. France Sales Analysis
- 7.4.6. Germany Sales Analysis
- 7.4.7. Italy Sales Analysis
- 7.4.8. Russia Sales Analysis
- 7.4.9. Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1. Overview, Historic and Forecast Data Sales Analysis
- 7.5.2. Asia Pacific by Segment Sales Analysis
- 7.5.3. Asia Pacific by Country Sales Analysis
- 7.5.4. China Sales Analysis
- 7.5.5. India Sales Analysis
- 7.5.6. Japan Sales Analysis
- 7.5.7. South Korea Sales Analysis
- 7.5.8. Australia Sales Analysis
- 7.5.9. South East Asia Sales Analysis
- 7.5.10. Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1. Overview, Historic and Forecast Data Sales Analysis
- 7.6.2. Latin America by Segment Sales Analysis
- 7.6.3. Latin America by Country Sales Analysis
- 7.6.4. Brazil Sales Analysis
- 7.6.5. Argentina Sales Analysis
- 7.6.6. Peru Sales Analysis
- 7.6.7. Chile Sales Analysis
- 7.6.8. Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1. Overview, Historic and Forecast Data Sales Analysis
- 7.7.2. Middle East & Africa by Segment Sales Analysis
- 7.7.3. Middle East & Africa by Country Sales Analysis
- 7.7.4. Saudi Arabia Sales Analysis
- 7.7.5. UAE Sales Analysis
- 7.7.6. Israel Sales Analysis
- 7.7.7. South Africa Sales Analysis
- 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE ANTI-ANXIETY DRUG COMPANIES

8.1. Anti-Anxiety Drug Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9 . COMPANY PROFILES OF ANTI-ANXIETY DRUG INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Pfizer Inc.
- 9.3.1. Company Overview
- 9.3.2. Company Revenue
- 9.3.3. Products
- 9.3.4. Recent Developments
9.4. Eli Lilly and Company
- 9.4.1. Company Overview
- 9.4.2. Company Revenue
- 9.4.3. Products
- 9.4.4. Recent Developments
9.5. GlaxoSmithKline plc
- 9.5.1. Company Overview
- 9.5.2. Company Revenue
- 9.5.3. Products
- 9.5.4. Recent Developments
9.6. Johnson & Johnson
- 9.6.1. Company Overview
- 9.6.2. Company Revenue
- 9.6.3. Products
- 9.6.4. Recent Developments
9.7. AstraZeneca plc
- 9.7.1. Company Overview
- 9.7.2. Company Revenue
- 9.7.3. Products
- 9.7.4. Recent Developments
9.8. Roche Holding AG
- 9.8.1. Company Overview
- 9.8.2. Company Revenue
- 9.8.3. Products
- 9.8.4. Recent Developments
9.9. Forest Laboratories (a subsidiary of Allergan
- 9.9.1. Company Overview
- 9.9.2. Company Revenue
- 9.9.3. Products
- 9.9.4. Recent Developments
9.10. now part of AbbVie)
- 9.10.1. Company Overview
- 9.10.2. Company Revenue
- 9.10.3. Products
- 9.10.4. Recent Developments
9.11. Bristol Myers Squibb Company
- 9.11.1. Company Overview
- 9.11.2. Company Revenue
- 9.11.3. Products
- 9.11.4. Recent Developments
9.12. Sanofi S.A.
- 9.12.1. Company Overview
- 9.12.2. Company Revenue
- 9.12.3. Products
- 9.12.4. Recent Developments
9.13. Lundbeck A/S
- 9.13.1. Company Overview
- 9.13.2. Company Revenue
- 9.13.3. Products
- 9.13.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies